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Introduction
Rheumatoid arthritis (RA) is an immune-mediated inflammatory 
disorder that manifests as painful articular disease and associated loss 
of joint function. Underlying the pathogenesis of RA is an imbalance 
in the complex network of pro- and anti-inflammatory cytokines, 
resulting in degenerative destruction of bone and articular cartilage. 
Whilst the pathophysiological symptoms of RA are cardinal signs of 
disease, there is evidence to suggest that a substantial burden of RA 
disease is linked to extra-articular comorbidities and psychosocial 
factors that may be mediated by systemic inflammatory processes [1].
To identify the extra-articular components of RA, it is necessary 
to validate novel methods capable of objectively assessing behavioral 
characteristics in inflammatory arthritis. Models of experimental 
arthritis with well-defined joint pathology [2-4], in combination with 
behavioral assessment, would enable classification of behaviors as 
dependent or independent of disease severity. Behavioral assessment 
within experimental arthritis research has, to date, been limited and 
focused primarily on gait evaluation [5-12]. Although open field test 
(OFT) techniques have been applied to experimental arthritis, these 
studies were limited by measuring activity at a single time-point 
[13,14] rather than in response to arthritis induction or progression. 
We propose that longitudinal assessment, using complementary 
tests, would deliver a more complete picture of behavior during 
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regulation of the hypothalamus-pituitary-adrenal (HPA) axis 
[29,30]. For example, relative levels of HPA hormones have been 
shown to predict response to biologic therapy in RA [30]. Secondly, 
mice deficient in anti-inflammatory interleukin-10 (Il10) exhibit 
depressive-like behavior [24]. Thirdly, the pro-inflammatory 
cytokine interleukin-6 (Il6) is able to stimulate the HPA axis [21], 
and can act at the level of the adrenal cortex [22]. Finally, high levels 
of pro-inflammatory cytokines have been measured in patients with 
depression [31,23] and neuropsychiatric changes, including anxiety, 
fatigue and depression, are prevalent in RA [32,33]. In summary, there 
is abundant evidence for bidirectional neuroendocrine-inflammation 
crosstalk in RA. However, the relationship between disease severity, 
behavior/mood and cytokine action remains unclear.
The aim of our study was to validate a novel longitudinal 
approach for behavioral evaluation of experimental arthritis in 
rodents, both during the acute phase of AIA and during recovery 
from the inflammatory processes, but prior to the onset of overt joint 
disease. By employing a range of sensitive behavioral tasks, we sought 
to identify distinct profiles of behavior that manifest either after the 
experimental arthritis. Such an approach would reveal global 
behavioral attributes driven by more subtle systemic changes, which 
may manifest independently from joint-specific processes.
Important considerations in assessing behavior in rodent models 
of RA are the classification and severity of disease. Poly-arthritic 
models inherently affect the general state of health of the animal, 
rendering behavioral studies difficult to interpret. Mono-arthritic 
models, such as the antigen-induced arthritis (AIA) model [3], 
provide a more suitable framework for disentangling the relationship 
between disease severity and global behavior status in arthritis. 
Disease severity can be manipulated by disrupting cytokine profiles. 
For example, mice deficient in pro-inflammatory [15,16] and anti-
inflammatory [4,17,18] cytokines present with differing degrees of 
synovial histopathology. Ultimately, these findings have led to the 
clinical introduction of biological drugs that target specific cytokine 
activities [19,20].
In addition to their important roles in mediating inflammatory 
processes, cytokines have been linked to mood disorders such as 
anxiety and depression [21-28] and implicated in neuroendocrine 
 
Figure 1: Novel application of combined behavioral measures to assess motor function and locomotor activity in experimental arthritis. (A) Schematic representation 
of longitudinal behavioral assessment during AIA. Blue arrows denote habituation to the behavioral tasks, 4 sessions of baseline measurement, and 7 testing days; 
(B) Significantly greater knee swelling in AIA-injected mice compared to PBS-injected mice; (C) No significant effect of PBS or AIA injection on stride length; (D) 
Latency to turn is not significantly different between the groups; (E) AIA-treated mice transiently demonstrate significantly longer latency to traverse the balance 
beam than PBS-treated mice; (F & G) AIA injection induced a significant transient increase in the number of foot slips made by both hind limbs; (H) Open field 
testing revealed a transient reduction in total distance moved and (I) time spent moving in the AIA-treated group compared to the PBS-treated group. Tracks show 
representative movement (black line) on day 2 post injection, when the AIA-injected group are significantly less active that the PBS-injected group. 
B–baseline testing day; Graphs represent mean ± SEM; Significant effect of Group: *p ≤ 0.05; Significant Group*Day interaction:  $$p ≤ 0.01, $$$p ≤ 0.001.
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acute, transient joint swelling or as a result of more subtle systemic 
changes that manifest post-AIA. To achieve this, we first compared 
wild-type (WT) mice with and without AIA to identify behavioral 
tasks sensitive to AIA. Secondly, we compared WT to Il10-/- mice, 
which exhibited similar levels of swelling and joint pathology up to 
15 days post-AIA as WT mice, but importantly, are thought to have 
different intrinsic immune responses [4]. Our decision to examine 
behavior up to, but not beyond, 15 days was based on our finding 
that joint pathology is comparable between WT and Il10-/- mice up 
to 15 days post-AIA. However, after that, changes in behavior may 
be driven by overt joint degeneration and not by the more subtle, 
systemic immune or hormonal alterations that manifest after AIA. 
Lastly, we used qPCR analysis of HPA axis tissues to reveal systemic 
changes that may underlie the extra-articular behavioral changes 
evident long-term in Il10-/- mice post-AIA.
Methods
Mice
For the behavioral experiment, fourteen male WT C57BL/6 
(Charles River, UK) and eight Il10-/- (C57BL/6 background, Jackson 
Laboratory, ME) were housed in groups of 3-5 and maintained on 
a 14:10-h light/dark cycle, with food and water available ad libitum. 
Experiments were performed on 8–12 week old mice.
A second cohort of male mice, consisting of 6 WT and 6 IL-10-/- mice, 
8-12 weeks old, were utilised for the investigation of gene expression 
within the HPA axis 3 days post AIA injection. These mice were housed 
in identical conditions to those utilised for behavioral analysis.
All experiments using animals were conducted in compliance 
with the UK Animals (Scientific Procedures) Act 1986 and ethical 
approval was assured through approval of UK Home Office Project 
License PPL-30/2928.
Antigen induced arthritis (AIA)
Mice were immunized by subcutaneous administration of 100 µl 
methylated bovine serum albumin (mBSA; 1 mg/ml, Sigma-Aldrich) 
emulsified in complete Freund’s adjuvant (CFA, Sigma-Aldrich). Mice 
were injected i.p. with 200 ng of heat-inactivated Bordetella pertussis 
toxin (Sigma-Aldrich). The immune response was boosted after 7 
days with identical administration of mBSA/CFA. Inflammatory 
arthritis was induced 21 days after the initial immunizations by intra-
articular administration of 10 µl mBSA (10 mg/ml) into the right 
hind knee joint. For the WT-PBS group, 10 µl phosphate buffered 
saline (PBS) was injected into the knee joint. Swelling was monitored 
by measuring knee joint diameter using a POCO 2T micrometer 
(Kroeplin), and recorded as the difference between right (inflamed) 
and left (contralateral) diameters. Knee joints were harvested at day 
15 post-AIA for histopathological assessment of disease severity 
(arthritic index).
Longitudinal behavioral assessment
A within-subjects design was chosen for this study, in order to 
observe the effect of arthritis onset within the same mouse. A within-
subjects design is particularly robust insofar as a direct comparison 
can be made with and without arthritis within the same host. WT 
mice were randomly assigned to receive AIA or PBS. All Il10-/- mice 
received AIA.
All mice were habituated to the open field apparatus over two 
days prior to the start of behavioral testing (Figure 1A). To establish 
the baseline behaviors of WT and Il10-/- mice in open field tests (OFT) 
and balance beam assessments, all mice were tested 4 times, over a 
period of 18 days, prior to the onset of AIA. Two behavioral tests were 
conducted before the immunization with BSA, and two behavioral 
tests were conducted after the mBSA injections (Figure 1A). For 
footprint analysis, two sessions were conducted to obtain baseline 
data, at 3 days and 1 day pre-AIA induction. Behavior was found to 
be consistent over this 18 day pre-AIA period for both genotypes on 
all tasks (see results section below for statistical analyses).
Each day, mice were assessed in the same order: animal distress 
rating/weighing, balance beam, OFT, footprint analysis. Four 
successive time-points post-AIA were chosen to capture behavioral 
alterations associated with acute inflammation, followed by 3 further 
time points up to 14 days post-AIA. Thus, behavioral testing was 
performed over 4 sessions during the 18 day pre-AIA period and 
for 7 sessions over the 14 day post-AIA period (Figure 1A). Mice 
were perfused on day 15. The end-point, day 15, was determined by 
previously published data showing that up to day 15 post-AIA, Il10-
/- mice were indistinguishable from WT mice on all measures of the 
arthritic index [4]. However, given that Greenhill et al. report that 
long-term differences in the extent of disease pathology emerge by 
day 28 post-AIA [4], we hypothesized that subtle, perhaps systemic, 
changes induced in the Il10-/- mice by the AIA may be revealed using 
the behavioral assays utilized here, which haven’t previously been 
detectable.
Elevated balance beam
The apparatus consisted of a tapered beam (0.5-1.5 cm) with a 0.5 
cm ledge that was situated 2 cm below the running surface. The bean 
was 100 cm long and angled at 17°. Mice were pre-trained to run up 
the beam to a goal-box. During testing, mice were placed at the lower 
end, facing away from the running surface. The turning time was 
recorded as a measure of motor coordination and the time to traverse 
indexed walking difficulty. The number of foot slips made by each 
limb was recorded as a measure of balance. Each mouse underwent 
three trials per day.
Open field test
Mice were placed in the middle of the arena (80 × 80 × 40 cm) and 
allowed to explore for 10 min. The arena was uniformly illuminated 
and the arena was always located in the same room. Two “locomotor” 
parameters were calculated: distance travelled and duration moving. 
After dividing the OFT arena into a central and a peripheral zone, 
two further anxiety-related parameters were calculated: the amount 
of time spent within, and the number of entries into, the central zone.
Monitoring of behavioral responses in the open field test
Behavior was recorded by a video camera, attached to a PC-based 
data recorder, and analyzed using EthoVision tracking software 
(Noldus Information Systems, The Netherlands).
Footprint analysis
Mice walked along a custom-built walkway on strips of paper (60 
× 10 cm). Their front and hind paws were painted with red and blue 
paint, respectively. Three series were recorded per day. Stride length 
was defined as the distance between feet of the left and right stepping 
cycle.
Animal Distress Score
An animal Distress Scoring system was used to monitor changes 
in health and wellbeing pre- and post-AIA in WT and Il10-/- mice 
[34]. This rating system considers several aspects of health, including 
weight, appearance, clinical symptoms, natural behavior and 
provoked behavior. Each category has a scale of 0-3, with ‘0’ denoting 
normal health and ‘3’ conveying a severe health condition. The 
appearance of the mouse may score ‘0’ if normal, ‘1’ if a general lack 
of grooming, ‘2’ where coat starring and/or ocular or nasal discharge 
is evident. ‘3’ when piloerection and hunching are observed. Clinical 
symptoms may not be present (0), or may be slight (1; pallor, 
diminished activity), moderate (2; weight loss, polyurea, diarrhoea) or 
severe (3; immobility, abnormal gait, fitting). Assessment of natural 
behaviors may reveal (0) normal behavior, (1) minor changes, (2) less 
mobile/alert, isolated or (3) vocalization, self-mutilation, restlessness/
stillness. Lastly, Provoked behavior may be (0) normal, (1) slightly 
depressed or exaggerated response, (2) moderate changes in expected 
behavior or (3) a violent reaction or very weak/precomatose response. 
Weights are also monitored and rated if changed. Each day, the score 
is adjusted if a 3 is assigned more than once, by adding 1 point per 
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3 score. Finally, 0-4 is considered normal behavior, 5-9 reveals that 
the mouse requires carefully daily monitoring and > 10 determines 
suffering and the need for termination.
Histology
Joints were fixed in neutral buffered formalin saline, decalcified 
with formic acid at 4°C and embedded in paraffin. Parasagittal 
sections (8 µm) were stained with hematoxylin, safranin-O and 
fast green. Disease severity was scored according to arthritic index, 
which comprises four components: sub-synovial inflammation (0-5); 
synovial exudate (0-3); hyperplasia and pannus formation (0-3) and 
articular cartilage or sub-chondral bone erosion (0-3). Scores were 
taken as the average of two observers blinded to the experimental 
design.
HPA axis evaluation by Quantitative RT-PCR
A second cohort of WT and IL-10-/- mice were used to investigate 
the impact of IL-10 deficiency on gene expression within the HPA 
axis following AIA. 6 mice of each genotype received AIA injections. 
Mice were euthanized by cervical dislocation 3 days post-AIA and 
the hypothalamus, pituitary and adrenal cortex were rapidly dissected 
and placed into RNAlater (Ambion) to inactivate RNAses. Following 
an overnight incubation at 4°C, tissues in RNAlater were transferred 
to a -80°C freezer for storage until RNA extraction. Total RNA was 
extracted from dissected tissues using the RNeasy lipid extraction kit 
(Qiagen, UK).
Quantitative PCR
200 ng of total RNA was reverse transcribed in a 20 ul reaction 
for 1h at 45°C using the AffinityScript kit (Agilent, UK). 2 µl cDNA 
was amplified in a 20 µl reaction volume using Brilliant III ultrafast 
qPCR master mix reagents (Agilent). PCR products were detected 
using dual-labeled (FAM/BHQ1) hybridization probes specific to 
each of the cDNAs (MWG/Eurofins, Germany). Gene changes in 
neuroendocrine signatures within tissues from the HPA axis were 
assessed by qPCR at day 3 following AIA onset. Expression of 
Nr3c1, Crh, Tnfrsf1a, Pomc, Mc2r and Il6 was quantified in HPA 
axis RNA samples relative to a geometric mean of mRNAs for the 
reference genes Gapdh, Sdha and Hprt1. See Supplementary 1 for 
oligonucleotide primer sequences and standards. Oligonucleotide 
primers were used at a concentration of 200 nM. Dual-labeled probes 
were used at 500 nM. PCR was performed using the M × 3000P 
platform (Agilent) using the following conditions: 45 cycles of 95°C 
for 12s and 60°C for 35s.
Statistics
Statistical analyses were performed using Prism (v6, GraphPad 
Software Inc.) and SPSS (v20, IBM). Behavioral and swelling data 
were analyzed using Repeated Measures ANOVA, with Group 
and Day as factors. Where an interaction between Group × Day 
was found to be significant, analysis of the simple effects was 
undertaken with a restricted ANOVA. Post-hoc effects were 
analyzed with the addition of a bonferroni correction for multiple 
comparisons, to ensure appropriate stringency. Histological 
data were analyzed using Univariate ANOVA, with Group as 
the between-subjects factor. The qPCR data were analyzed using 
unpaired t-test. Swelling and behavioral data are graphically 
depicted with the full 18 day pre-AIA period (consisting of 4 
baseline behavioral test sessions) to demonstrate the stability of 
the behavioral performance of the WT and Il10-/- mice. The 14 
day post-AIA period (consisting of 7 test days) is then depicted. 
An analysis was conducted on the baseline data to determine 
the pattern of performance on the task prior to AIA onset and 
to identify any baseline differences between WT and Il10-/- mice. 
Then an analysis of the post-AIA data was conducted to determine 
the effect of the AIA insult on behavioral performance.
To investigate the interaction between loss of IL-10 and arthritis 
induction on behavioral performance, an analysis compared data 
obtained during the baseline training against data obtained from 
the final week of AIA (Figure 2). Datasets from all four days within 
the baseline period (-18, -16, -3, -1) were averaged and compared 
against the average of datasets for the final two days of assessment 
post-AIA (+10, +14). The percentage change post-AIA, relative to the 
baseline period, was calculated. Independent samples t-tests explored 
differences in performance between the genotypes.
Results
Identification of acute behavioral impairments after AIA 
induction in WT mice
Schematic depicting the experimental design for longitudinal 
assessment of AIA (Figure 1). At baseline (prior to AIA onset), no 
differences in swelling, stride length, performance on the balance 
beam, nor distance travelled in the OFT were evident between the WT 
groups [maximum: F1,12 = 2.81, n.s.]. Although a mild but significant 
difference was revealed on the duration of time spent moving in 
the OFT [Group: F1,12 = 6.08, p < 0.05], overall the groups were well 
matched at baseline.
Mice receiving i.a. injection of mBSA (WT-AIA) displayed 
significant joint swelling from day 1 post AIA. While acute alterations in 
 
Figure 2: Induction of AIA generates subtle clinical symptoms in IL-10-
/- mice. (A) Application of the Animal Distress Scoring system revealed no 
difference in appearance at baseline, but a subtle change in appearance in 
IL-10-/- mice after AIA; (B) Very mild clinical symptoms were observed in IL-
10-/- mice at baseline, but these fell within the range of normal behaviors (0-4 
score). Post-AIA, both WT and IL-10-/- mice presented with a mild increase in 
clinical symptoms, which were sufficiently subtle to remain within the range of 
normal behaviors. No changes were observed post-AIA for either genotype 
on the categories of weight, natural behaviors or provoked behaviors (data 
not shown). Significant effect of Group: *p ≤ 0.05; Significant Group*Day 
interaction: $$$p ≤ 0.001.
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joint swelling continued for 7 days post arthritis induction, this response 
showed no relationship to changes in behavior. In contrast, control mice 
receiving PBS (WT-PBS) showed no joint swelling [Figure 1B; Group: 
F1,12 = 69.12, p < 0.001; Group × Day: F7,84 = 45.58, p < 0.001].
While neither the stride length [Figure 1C; F < 1], nor the latency 
to turn [Figure 1D; F < 1] on the balance beam were affected by antigen 
challenge, WT mice with AIA were slower to traverse the length of 
the balance beam than WT-PBS mice, an effect that lasted until day 4 
of AIA [Figure 1E; Group × Day: F7,84 = 6.72, p < 0.01]. WT-AIA mice 
demonstrated a significantly higher number of foot slips of both the 
ipsilateral (right) and the contralateral (left) hind limbs, an effect which 
lasted for 3 days post-AIA in both hind limbs [Figure 1(F & G); min: 
Group × Day: F7,84 = 3.30, p < 0.01]. This motor deficit was specific to 
the hind limbs. No significant increase in the number of foot slips were 
observed for the front limbs after antigen challenge (data not shown; 
maximum F1,12 = 2.49, p > 0.05). In OPF assessments, the total distance 
travelled was transiently reduced by the onset of AIA, returning to 
baseline levels by 4 days post-insult [Figure 1F; Group × Day: F7,84 
= 4.38, p < 0.001] and the duration of time spent moving was shorter 
in WT-AIA mice [Group × Day: F7,84 = 4.27, p < 0.001]. The indices of 
anxiety (quantified as entries into the inner zone and time spent in the 
inner zone) were not significantly altered after AIA [data not shown; 
maximum: Group: F1,12 = 2.70, all p’s n.s.].
All behavioral abnormalities in WT-AIA mice returned back to 
baseline by day 7 post AIA, when joint swelling had subsided.
Similar motor coordination deficits and articular joint 
pathology during acute AIA in WT and IL-10-deficient mice
There were found no overt differences in joint swelling or articular 
pathology as assessed by measurement of inflammatory infiltration and 
exudate, synovial hyperplasia and joint erosion in WT and Il10-/- mice. 
While the induction of disease in WT and Il10-/- mice promoted changes 
in joint swelling [maximum: F1,11 = 3.36, n.s.] and synovial inflammation 
[Figure 3(C & D); minimum: Group: F2,28 = 35.33, all p’s < 0.001; WT and 
Il10-/- AIA vs. WT-PBS, all p’s < 0.001], no difference in disease severity 
was observed between the two mouse genotypes [Figure 3(C & D); WT-
AIA vs Il10-/- AIA, all p’s n.s.]. On the balance beam test, the number 
of foot slips coincided with the development of knee swelling in the 
AIA treated right hind joint. Both Il10-/- and WT mice showed a similar 
number of foot slips in response to AIA [maximum: Group: F1,11 = 3.36, 
n.s.]. All mice slipped more often on the balance beam with both hind 
limbs [Figure 3A; minimum: Day: F6,66 = 8.75, p < 0.001] and significant 
swelling was observed in the knee joint after AIA induction [Figure 3B; 
Day: F6.66 = 85.45, p < 0.001].
Arthritis onset has a minimal impact on animal welfare
Application of the Animal Distress Scoring system revealed no 
substantive difference between WT and Il10-/- mice on either ‘natural’ 
or ‘provoked’ behaviors. This was true both before and after the onset 
of AIA [data not shown; maximum: Group: F2,28 = 3.25, n.s.]. A small 
difference was observed on the ‘clinical signs’ score between WT 
and Il10-/- mice at baseline [Figure 2A; Group: F2,18 = 5.05, p < 0.05]. 
However, this was extremely subtle and equated to < 1 on the clinical 
symptoms scale (0-4 = normal, 5-10 = mild symptoms).
However, following AIA onset, both WT-AIA and Il10-/- AIA 
mice experienced a fluctuation in clinical symptoms that reached 
approximately 1.7 on the scale, demonstrating a very mild effect of 
AIA on wellbeing [Group*Day: F14,126 = 3.39, p < 0.001]. No significant 
differences were revealed between WT-AIA and Il10-/- AIA mice, but 
 
Figure 3: Joint-specific processes during acute AIA are independent of IL-10. (A) Significant transient increase in number of footslips post AIA in both WT and 
IL-10-/- groups; (B) Significant increase in swelling due to AIA induction in both WT and IL-10-/- groups; (C) Evaluation of arthritic index, inflammation, exudate, 
hyperplasia, and erosion in AIA-induced knee joints of WT and IL-10-/- mice, compared to WT-PBS treated mice. Values are presented for individual joints taken 
at Day-15 post AIA; (D) Representative Safranin-O and Fast Green stained parasagittal joint sections taken on Day-15 for WT-PBS, WT-AIA and IL-10-/--AIA 
mice (scale bars, 500 μM). B–baseline testing day. Graphs represent mean ± SEM. Significant effect of Day: ###p ≤ 0.001; significant effect of Group: ***p ≤ 0.001.
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both these groups receiving AIA differed from WT-PBS mice.
The appearance rating did not differ between the groups at 
baseline [Figure 2B; Group: F2,18 = 1.00, n.s.]. However, post-AIA, 
there was a transient and subtle impact of the intervention on the 
appearance rating of Il10-/- mice only [Group*Day: F14,126 = 3.16, p = 
0.001].
Slight changes in appearance were also evident post-AIA in Il10-/- 
AIA mice only. These changes accounted for the difference in overall 
score observed at baseline [Figure 2C; Group: F2,18 = 7.56, p < 0.01] 
and post-AIA [Group*Day: F14,126 = 2.87, p = 0.001].
Arthritis induction promotes extra-articular changes in 
mobility and anxiety in Il10-/- mice.
Baseline behavioral performance: Prior to arthritic insult (at 
baseline), the loss of IL-10 had no effect on stride length nor on 
the time to turn on the balance beam [Figure 4(A & C); maximum: 
Group: F1,11 = 6.07, n.s.]. The latency to traverse the balance beam was 
increased in Il10-/- AIA mice relative to WT-AIA mice [Figure 4D; 
Group: F1,11 = 70.16, p < 0.001]. Moreover, in the OFT, IL-10-/--AIA 
mice spent less time moving, travelled less far, entered into the inner 
zone fewer times and spent less time in the inner zone than WT-AIA 
mice [Figure 4(B,E & F); minimum: Group: F1,11 = 4.87, p = 0.05].
Importantly, however, prior to AIA insult, the behavior of the 
Il10-/- and WT mice was found to be consistent and stable across the 
18 baseline days on every behavioral task [maximum, both for OFT 
duration moving: Day: F3,33 = 2.84, n.s.; Day*Group: F3,33 = 2.83, n.s.]. 
The reduction in the latency to traverse the balance beam observed 
during the fourth session, after the elevated scores obtained in the 
first 3 sessions, is likely accounted for by improved experimenter 
technique with repeated practice.
Post-AIA behavioral performance: Stride length, as measured 
in the footprint test, was specifically reduced in IL-10-/--AIA mice, 
relative to WT-AIA mice [Figure 4A; Group: F1,11 = 5.46, p < 0.05]. 
By the final week, however, performance had returned to baseline 
for both genotypes [t11 = -0.05, n.s.]. Stance base width and hindpaw/
forepaw overlap were also measured throughout this experiment. No 
effects of IL-10 deficiency, nor effects of AIA, were evident on these 
aspects of gait (data not shown).
On the balance beam, the latency to turn was significantly 
increased in IL-10-/- mice post-AIA, relative to WT-AIA mice [Figure 
4C; Group: F1,11 = 5.02, p < 0.05]. Although by the final week of 
testing, a numerical increase in latency to turn was still evident in Il10-
/- AIA mice, this effect did not reach conventional levels of statistical 
significance [t11 = 1.28, n.s.].
Il10-/- AIA mice demonstrated an increased latency to traverse 
the beam [Figure 4D; Group: F1,11 = 22.50, p = 0.001], which was also 
evident at baseline. More interestingly, the significant effect of Day 
reveals the impact of AIA insult on performance [Day: F6,6 6= 3.82, 
p < 0.01]. Comparison of the latency data during the final week, as 
compared to the baseline period, reveals that both genotypes returned 
to baseline levels [t11 = -0.66, n.s.].
On the OFT, differences in performance were evident between 
the genotypes post-AIA on all measures, as was observed at baseline 
[Figure 4(B,E & F); minimum: Group: F1,11 = 15.06, p < 0.01]. Unlike 
at baseline, however, there was also a significant effect of Day on 
every measure, demonstrating the impact of the AIA on performance 
[minimum: Day: F6,66 = 3.52 p < 0.01]. Most importantly, on both 
measures of locomotor activity (distance travelled and duration 
moving), comparison of the activity levels during the final week, 
as compared to the baseline period, revealed a return to baseline 
 
Figure 4: Loss of IL-10 delays recovery of global behavioral deficits induced by AIA. (A) Significant reduction in stride length by IL-10-/- mice after AIA induction, 
which returns to baseline levels by the final week of testing; (C) The latency to turn on the balance beam is impaired post-AIA in IL-10-/--AIA mice but not WT mice; 
(D) IL-10-/--AIA mice take significantly longer than WT-AIA mice to traverse the balance beam at baseline and post-AIA; (B) Representative movement tracks 
(black line) of one WT-AIA and one IL-10-/--AIA mouse in OFT. Blue square represents arena border and red square denotes the inner and outer zones used to 
determine anxiety indices. (E & G) In the OFT, IL-10-/--AIA mice spent less time moving and travelled shorter distances both pre-AIA. However, locomotor behavior 
is disrupted in both WT and IL-10-/- mice post-AIA. Moreover, IL-10-/--AIA mice take longer to recover the activity deficit; (F & H) In the OFT, the indices of anxiety 
reveal overall differences between the genotypes, but both WT and IL-10-/--AIA mice demonstrate reduced time in, and entries into, the inner zone of the arena 
after AIA. IL-10-/--AIA mice show prolonged impairment on these measures. 
Graphs represent mean ± SEM. Significant effect of Group: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; Significant effect of Day: ##p ≤ 0.01, ###p ≤ 0.001. 
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performance for WT-AIA mice, while Il10-/- AIA mice were still 
significantly affected by the AIA intervention during the second week 
post-AIA [t11 = -3.57 & -3.18, respectively, p’s < 0.01].
Moreover, on both measures of anxiety (time in inner zone and 
entries into inner zone), Il10-/- AIA mice were impaired for longer 
than WT-AIA mice. By the final week of testing, the time spent in 
the inner zone was severely reduced in Il10-/- -AIA mice, compared to 
WT-AIA mice [t11 = -2.48, p < 0.05]. Also, while the number of entries 
into the inner zone had returned to baseline levels for WT-AIA mice, 
the Il10-/- AIA mice were still significantly impaired by the second 
week of post-AIA behavioral testing [t11 = -2.48, p < 0.05]. Overall, 
the results demonstrate that AIA induction initiates global, extra-
articular behavioral abnormalities in both WT and Il10-/- mice, and 
that specific subtle interactions between IL-10 deficiency and AIA can 
be detected on behavioral performance.
Up-regulation of specific HPA axis signatures is associated 
with IL-10 dependent increased anxiety index
At day 3 post AIA induction, mRNA expression of specific HPA 
axis regulators was elevated in Il10-/- -AIA mice compared to WT-AIA 
controls: hypothalamic glucocorticoid receptor, Nc3r1 [Figure 5A, t8 
= 2.63, p < 0.05]; pituitary pro-opiomelanocortin, Pomc [Figure 5B, 
t10 = 2.74, p < 0.05]; and adrenal cortex adrenocorticotropin hormone 
receptor, Mc2r [Figure 5C, t10 = 3.52, p < 0.01]. Other HPA signatures 
such as the precursor peptide for corticotropin-releasing hormone 
precursor, Crh, were not significantly different at day 3 [Figure 5A, n.s.]. 
Importantly, the differences observed at day 3 of AIA are not simply 
explained by IL-10 deficiency, as there were no significant differences 
between genotypes in the absence of AIA (n.s., for all effects of genotype 
at baseline; data not shown). Notably, a concurrent increase in adrenal 
pro-inflammatory IL-6 expression, il6, was measured in the Il10-/- AIA 
group (Figure 5C, t10 = 3.55, p < 0.01), compared to the WT-AIA group. 
Other inflammatory markers, such as tumor necrosis factor receptor 1A, 
TNFR1a, were unaltered by IL 10 deficiency (Figure 5, maximum t8 = 
0.96, n.s.).
Discussion
This study provides novel insight into rodent behavior during 
experimental arthritis by applying behavioral neuroscience 
methodologies for longitudinal assessment of AIA. We utilized the 
OFT, footprint analysis and the balance beam test to assess the impact 
of arthritic insult, and its interaction with loss of IL-10, on behavior 
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over 14 days. This novel application of select behavioral tasks has 
revealed several interesting phenomena. Firstly, these tasks identified 
changes in behavior that occurred as a result of arthritis but, more 
importantly, they can distinguish between joint-specific processes 
and more global, systemic changes in behavior. Mapping a timeline 
of behavior over two weeks also reveals transient dynamic changes 
that occur prior to the onset of chronic alterations.
From this study, we conclude, firstly, that the onset of arthritis 
causes acute, but transient, changes in swelling and motor 
performance, which affect balance and specific limb use in WT-
AIA mice. Consistent with previous reports [2-4], AIA caused a 
characteristic antigen-dependent swelling of injected knee joints. 
Results demonstrate that specific behavioral deficits coincide with 
acute indices of AIA, such as joint swelling. Thus, the novel application 
of complementary behavioral tasks in mice with experimental 
arthritis reveals acute alterations in motor and locomotor responses.
Secondly, Il10-/- -AIA mice demonstrated comparable changes 
in specific joint dysfunction to WT-AIA mice, as measured by the 
balance beam, knee swelling measurements and articular pathology 
indices. Thus, while deficits related to AIA were evident in joint 
swelling and footslips measures, loss of Il10 did not exacerbate these 
joint-specific processes during AIA.
Thirdly, arthritis onset has a minimal impact on animal welfare. 
Natural and provoked behaviors were not affected by the onset 
of AIA, but subtle changes in clinical symptoms and appearance 
were observed in WT-AIA and Il10-/- AIA mice. It is worth noting, 
however, that the magnitude of these changes was minor, since 
normal wellbeing registers between 0-4 on the rating scale, with 
mild/moderate changes ranging in between 5-9. Appearance changes 
averaged < 1 and clinical signs reached a maximum of 1.7 on the 
rating scale. Therefore, an interesting but subtle interaction between 
AIA and IL-10 deficiency was revealed using the Animal Distress 
Scale
Next, these data reveal, interestingly, arthritis induction 
promotes extra-articular changes in mobility and anxiety in Il10-/- 
mice. Il10-/- -AIA mice presented with more systemic, global changes 
in behavior, and recovery of function was prolonged relative to WT-
AIA mice. Over a longer term, Il10-/- AIA mice displayed shortened 
stride length, increased latency to turn on and traverse up the balance 
beam, a reduction in exploratory behavior, and fewer entries into the 
inner area of the OFT apparatus. Previous studies have shown that 
mice deficient in the anti-inflammatory cytokine IL-10 show a more 
sustained, long-term arthritic disease as compared to WT mice [4]. 
However, the extent of disease activity seen in WT and Il10-/- mice 
remains comparable during the first two weeks following arthritis 
induction [4]. Thus, these chronic behavioral alterations cannot 
simply be accounted for by direct changes in limb function since 
joint-specific impairments, such as knee swelling and hind limb foot 
slips, returned to baseline in a similar manner in WT-AIA and Il10-/- 
AIA mice. The observation that Il10-/- mice have prolonged behavioral 
and anxiety-related impairments post-AIA may be important for 
addressing the high prevalence of mood disorders in patients with RA 
[33,34]. Il10 deficiency is known to have profound immune outcomes 
that may influence the inflammatory control of neuropsychological 
behaviors. In addition to its role in modulating the severity of chronic 
experimental arthritis [4,17], IL-10 has been linked with anxiety and 
mood in both rodents and patients [22,24]. Although IL-10 plays a 
role in RA [19] and has previously been linked with mood disorders 
[24-26], there has been insufficient evidence for a specific role for 
IL-10 in regulating behavior during inflammatory arthritis. Here, we 
show that IL-10 deficiency altered the global motor and locomotor 
phenotype in mice that received AIA. Taken together, these results 
suggest reduced activity and heightened anxiety levels due to the 
interaction of IL-10 deficiency and AIA.
Finally, we found that IL-10 dependent increases in anxiety are 
associated with the up-regulation of specific HPA axis signatures. The 
IL-10 dependent delay in recovery of global locomotor and anxiety-
related behaviors identified using open field and balance beam 
techniques (Figure 2) occurred in the absence of any overt differences 
in articular pathology at day 15 post AIA. Whereas WT mice begin 
recovery earlier, the Il10-/- mice display longer-term behavioral 
impairments. We therefore hypothesized that the IL-10-dependent 
global behavioral abnormalities observed during AIA were mediated 
by systemic processes, occurring outside the joint. Specifically, we 
focused on neuroendocrine signatures from HPA axis tissues. The 
results revealed increased mRNA expression of the specific HPA 
axis regulators Nc3r1, Pomc, Mc2r in Il10-/- -AIA mice compared to 
WT-AIA controls at day 3 post AIA induction. Moreover, specific 
regulation of neuroendocrine pathways by IL-6, as determined here, 
is supported by previous studies showing stimulation of the HPA axis 
by IL-6 [20-21].
Thus, in this study, it has been possible for the first time to 
determine the role of IL-10 in behavioral control during experimental 
arthritis. The observation that IL-10 deficiency delays the recovery 
of global behaviors, independent of specific joint impairment, may 
be explained by aberrant inflammatory activation in Il10-/- mice 
[4,17], or abnormal cytokine control of neuroendocrine processes 
[25]. Addressing these types of questions is becoming increasingly 
important for understanding the extra-articular comorbidities [1] 
and psychosocial factors [33,35] associated with RA.
When exploring behavioral responses in rodent models 
of chronic disease it is essential to consider the nature of the 
inflammation (i.e., localised vs. systemic) and the severity of disease 
(i.e., the histopathology). Systemic models of inflammatory disease 
(e.g. polyarticular models of arthritis) often have a more severe 
impact on animal health and welfare. For example, these models often 
necessitate the use of analgesia in the protocol. This makes behavioral 
studies more challenging and difficult to interpret. A monoarticular 
model of antigen-induced arthritis (AIA) was therefore adopted, 
where synovitis is established in one knee. This model shows 98-
100% penetrance in C57/bl6 mice and the development of disease is 
well-characterized [10,13,16]. While studies in AIA have documented 
changes in joint pathology, gait analysis and loss of joint movement, 
the impact of AIA on animal behavior has never been tested. Previous 
behavioral assessments of experimental arthritis were limited to 
either single-technique gait evaluation [5-12] or single-trial OFT 
assessment [13-14].
Finally, we propose a potential mechanism underlying the delayed 
recovery of global behaviors observed in Il10-/- mice. RT-qPCR 
expression profiling of HPA axis tissue 3 days post-AIA identified IL-
10-dependent changes in gene expression in each of the three tissues. 
Specifically, Nc3r1, Pomc, and Mc2r mRNAs were expressed at higher 
levels in Il10-/- mice after AIA compared to WT-AIA mice. Whilst 
adrenal IL-6 mRNA expression was up-regulated at the same time-
point in Il10-/- mice, TNFR1a mRNA expression in all HPA tissues did 
not differ between WT and Il10-/- mice. These data raise the possibility 
that, in the absence of IL-10, AIA elevates levels of IL-6 within the 
adrenal cortex that may act, potentially locally, to modulate gene 
expression within the HPA axis, thereby altering axis function [22]. 
Further validation of this hypothesis is required in order to determine 
the precise mechanism of action.
Conclusions
In summary, we have shown that the application of behavioral 
techniques to experimental arthritis can reveal novel and interesting 
phenomena that could fundamentally shift the landscape of RA 
treatment. Inclusion of longitudinal behavioral assessment in our 
experimental design enabled us to disentangle behaviors which are 
driven by articular insult, from those induced by systemic, extra-
articular changes that are more purely induced by interaction 
between IL-10 deficiency and AIA. Although we have focused on 
IL-10 deficiency in the first instance, there is great potential for this 
type of work to unravel new mechanisms to inform new strategies for 
reducing the extra-articular disease burden [1].
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Supplementary Information
Quantitative PCR
For quantifying Il6 and Tnfrsf1a expression, standard curves were generated for every real time PCR run for Il6, Tnfrsf1a and reference 
gene cDNAs, by using serial threefold dilutions of reverse transcribed adult mouse spleen total RNA (Zyagen, San Diego, USA). For quantifying 
Nr3c1, Crh, Pomc and Mc2r expression, standard curves were generated for every real time PCR run for Nr3c1, Crh, Pomc, Mc2r and reference 
gene cDNAs, by using serial threefold dilutions of reverse transcribed adult mouse brain total RNA (Zyagen, San Diego, USA). Relative mRNA 
levels were quantified in four to six separate sets of each tissue dissected from each genotype. Primer and probe sequences were designed using 
Beacon Designer software (Premier Biosoft, Palo Alto, USA).
Primer /probe sequences Accession number QPCR product length/bp
Crh forward: 5′-ATC TCA CCT TCC ACC TTC- 3′
Crh reverse: 5′-CAA CAT TTC ATT TCC CGA TAA-3′
Crh probe: 5'-FAM-CTC CAT CAG TTT CCT GTT GCT GT-BHQ1-3'
NM_205769.2 113
Il6 forward: 5′-CAG AAA CCG CTA TGA AGT-3′
Il6 reverse: 5′-CTT GTG AAG TAG GGA AGG-3′
Il6 probe: 5′- FAM-TTG TCA CCA GCA TCA GTC C-BHQ1-3′
NM_031168.1 99
Mc2r forward: 5′-TGA AGC ATA TTA TCA ATT CGT AT-3′
Mc2r reverse: 5′-ACT ACA TCA GGA CAA TCG-3′
Mc2r probe: 5′-FAM-CAC ACC AAT GAC ACC GCA AGA-BHQ1-3′
NM_001271716.1 73
Nr3c1 forward: 5'-GGT TGG AGA TCA TAC AGA-3'
Nr3c1 reverse: 5'-CTT TGT AAT TCA GTG GAG AT-3'
Nr3c1probe: 5'-FAM-CAA GTG GAA ACC TGC TAT GCT-BHQ1-3'
NM_006525658.1 140
Pomc forward: 5′-AAG AAC GCC ATC ATC AAG-3′
Pomc reverse: 5′-TCC TAA CAC AGG TAA CTC TA-3′
Pomc probe: 5′-FAM-TAG AGG TCA TCA GCT CGC C-BHQ1-3′
NM_001278581.1 129
Tnfrsf1a forward: 5′-TTC CCA GAA TTA CCT CAG-3′
Tnfrsf1a reverse: 5′-AAC TGG TTC TCC TTA CAG-3′
Tnfrsf1a probe: 5′- FAM-CAC CGT GTC CTT GTC AGC-BHQ1-3′
NM_011609.4 123
Gapdh forward: 5′-GAG AAA CCT GCC AAG TAT G-3′
Gapdh reverse: 5′-GGA GTT GCT GTT GAA GTC-3′
Gapdh probe: 5′-FAM-AGA CAA CCT GGT CCT CAG TGT-BHQ1-3
NM_001289726.1 122
Hprt1 forward: 5′-TTA AGC AGT ACA GCC CCA AAA TG-3′
Hprt1 reverse: 5′-AAG TCT GGC CTG TAT CCA ACA C-3′
Hrpt1 probe: 5′-FAM-TCG AGA GGT CCT TTT CAC CAG CAA G-BHQ1-3′
NM_013556.2 85
Sdha forward: 5′-GGA ACA CTC CAA AAA CAG-3′
Sdha reverse: 5′-CCA CAG CAT CAA ATT CAT-3′
Sdha probe: 5′-FAM-CCT GCG GCT TTC ACT TCT CT-BHQ1-3
NM_023281.1 127
